Recent Transactions

14-Nov-16
$NA
Japan, Australia flags
Target: 

Lion’s Australian Premium Wine Business – Fine Wine Partners

Australia flag
Acquiror: 
Accolade Wines

Advised Lion, a leading Australasian food and beverage company wholly owned by Japanese conglomerate Kirin, on the sale of its Australian wine business Fine Wine Partners to Accolade Wines, a portfolio company of CHAMP Private Equity

03-Nov-16
$3.3 billion
United States flag
Target: 

Metaldyne Performance Group, Inc.

United States flag
Acquiror: 
American Axle & Manufacturing Holdings, Inc.

Advised American Axle & Manufacturing Holdings, Inc., a leading manufacturer of driveline and drivetrain systems and related components and metal-formed products, on the acquisition of Metaldyne Performance Group, Inc., a provider of highly-engineered lightweight components for use in powertrain and suspension applications for the global light, commercial and industrial vehicle markets

03-Nov-16
$NA
Switzerland flag
Target: 

Fragrance Resources Group

United States flag
Acquiror: 
International Flavors & Fragrances Inc.

Advised IFF, one of the world’s largest flavors and fragrances businesses, on the acquisition of Fragrance Resources Group, a family-owned fragrance company headquartered in Switzerland

17-Oct-16
$1.4 billion
United States flag
Target: 

Save-A-Lot

Canada flag
Acquiror: 
Affiliate of Onex Corporation

Advised SUPERVALU, Inc., one of the largest grocery wholesalers and retailers in the US, on the sale of its Save-A-Lot business, a leading hard-discount grocery retailer in the U.S., to an affiliate of Onex Corporation 

05-Oct-16
$775 million
U.K., Ireland flags
Target: 

Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Accord Healthcare Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m) 

Pages

show all